Communication from the Ministry of Foreign Affairs No 19 / 2025 Coll.
Communication from the Ministry of Foreign Affairs amending and supplementing the Communication from the Ministry of Foreign Affairs No. 58 / 2007 Coll. and No. 46 / 2008 Coll. s.
Valid
Effective from 18.06.2024
19
COMMUNICATION
Ministry of Foreign Affairs,
amending and supplementing the Communication of the Ministry of Foreign Affairs No 58 / 2007 Coll. s. and No 46 / 2008 Coll. s. s.
The Ministry of Foreign Affairs announces that on 1 October 2023 the approval of the new text of Annex I - List of prohibited substances and methods of doping for 2024 - International Standard of the International Convention against Doping in Sport was notified by the Director-General of UNESCO.
With new text of the Annex I approved the Parliament of the Czech Republic and the President of the Republic signed the instrument of acceptance of amendments to Annex I by the Czech Republic.
New version of the Annex I entered into force in accordance with Article 34 (3) of the Convention on 1 January 2024, entered into force for the Czech Republic on 18 June 2024 and replaced Annex I for 2023, valid from 1 January 2023, which entered into force for the Czech Republic on 22 June 2023 and was published under No 32 / 2023 Coll.
The English version of Annex I for 2024 and its translation into the Czech language are published simultaneously.
Minister:
z. JUDr. Smolek, Ph.D., LL.M., v. r.
Head of Legal and Consular Section
Příloha č. 1
Annex No 1
Translation of international contract into Czech language
Introduction
The list of prohibited substances and methods of doping is a mandatory International Standard within the World Anti-doping Programme.
The list shall be updated annually following an extensive consultation process, facilitated by the World Anti-Doping Agency (WADA). The list shall be effective from 1 January 2024.
The official text of the List of prohibited substances and methods will be stored by WADA and published in English and French. In the event of any discrepancies between the English and French texts, the text shall be authentic in English.
The following are some terms used in this List of prohibited substances and methods.
Prohibited In competition
If WADA has not approved a different period for the sport, the period During the competition, in principle, the period starting just before midnight (at 11: 59 p.m.) on the day preceding the competition to be held by Sportávec until the end of the competition and the sampling process.
Forbidden all the time
This means that the substance or method is prohibited In the competition and outside the competition as defined in the Codex.
Specific and Non-specific
Pursuant to Article 4.2.2 of the World Anti-doping Code, "for the purposes of applying Article 10, all Prohibited Substances will be specific substances, except those identified in the List of Prohibited Substances and Doping Methods. No Forbidden Method shall be the Specific Method unless it is specifically identified as the Specific Method in the List. 'According to the comment on the article" Specific substances and specific methods referred to in Article 4.2.2 should in no way be considered as less important or less dangerous than other doping substances or methods. These are substances and methods likely to be used or used for a purpose other than to improve sport performance.'
Additives
In accordance with Article 4.2.3 of the Code, addicts are defined as substances which are identified as such because of their frequent abuse in a society outside sport. The following substances are referred to as addicts: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA / "ecstasy"), tetrahydrocarbinol (THC).
S0 NOT APPROVED
_
All the prohibited substances in this class are specific substances.
Any pharmacological substance not covered by any of the following sections of the List which is currently not approved by any government health regulatory authority for medicinal use in humans (e.g. medicinal products in preclinical or clinical development or the development of which has been terminated, synthetic drugs, substances approved for veterinary use only) is still prohibited.
This class includes many different substances, including BPC-157, 2,4-dinitrophenol (DNP) and troponin activators (e.g. Reldesemtiv and Tirasemtiv).
S1 ANABOLIC SUBSTANCES
_
All prohibited substances in this class are non-specific substances.
Anabolic agents are prohibited.
_
For exogenous administration including, but not limited to:
- (5-Chloro-1-enestone)
and other substances with similar chemical structure or similar biological effects.
S1.2. OTHER ANABOLIC SUBSTANCES
Including:
Clenbuterol, osilodrostat, ractopamine, selective androgen receptor modulators [SARM, e. g. andarin, enobosarm (ostarin), LGD-4033 (ligandrol), RAD140, S-23 and YK-11], zeranol and zilpaterol.
S2 PEPTIDE HORMONES, GROWTH FACTORS, RELEVANT SUBSTANCES AND MIMETIC
_
All prohibited substances in this class are non-specific substances.
The following substances and other substances with a similar chemical structure or similar biological effects are prohibited.
S2.1. ERYTROPOETINES (EPO) AND SUBSTANCES INCLUDING ERYTROPOESIA
Including:
S2.1.1. erythropoietin receptor agonists such as darbepoetins (dEPO); erythropoietins (EPO); EPO-based compounds [e. g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO- mimetic agents and their compounds, e.g. CNTO-530, peginatide. S2.1.2. Activated hypoxia inducing factor (HIF), e.g. cobalt; daprodustat (GSK1278863); IOX2; molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon.S2.1.3 GATA inhibitors, e.g. K-11706. S2.1.4Inhibitors of transforming growth factor beta (TGF-β), e. g. lupatercept; sotatercept. S2.1.5Agonists of the congenital correction receptor, e.g. asialo EPO; carbamylated EPO (CEPO).
S2.2. PEPTIDE HORMONES AND THEIR OPENING FACTORS
S2.2.1. Peptides stimulating testosterone in men including: • chorionic gonadotropin (CG), • luteinising hormone (LH), • hormone releasing gonadotropin (GnRH, gonadorelin) and its agonist analogues (e. g. buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin), • kisspeptin and its agonist analogues. S2.2.2. Corticotrophins and their release factors such as corticoline and tetracosactide. S2.2.3Growth hormone (GH), its analogues and fragments, including: • Growth hormone analogues such as lonapegsomatropin, somapacitan and somatrogon, • Growth hormone fragments such as AOD-9604 and hGH 176-191. S2.2.4. Growth hormone release factors, including: • Growth hormone release hormone (GHRH) and its analogues, such as CJC-1293, CJC-1295, sermorelin and temorelin, • Growth hormone secretion (GHS) and their mimetics [e. g. anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin], peptides releasing GH (GHRP) [e. g. alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5 and GHRP-6].
S2.3. GROWTH FACTORS AND GROWTH FACTORS
Including:
• Growth factor 1 similar to insulin (IGF-1, mecasermin) and its analogues • Mechanical growth factor (MGF) • Platelet-derived growth factor (PDGF) • Thymosine-β4 and its derivatives, e. g. TB-500 • Vasular-endothelial growth factor (VEGF)
and other growth factors or growth factors modulators affecting protein synthesis / degradation in muscles, tendons or tissues, vascularisation, energy use, regenerative capacity or muscle fibre types.
S3 BETA-2 AGONISTS
_
All the prohibited substances in this class are specific substances.
All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited.
Including:
• arformoterol • indacaterol • reproterol • tretoquinol (trimethoquinol) • phenoterol • levosalbutamol • salbutamol • tulobuterol • formoterol • olodaterol • salmeterol • vilanterol • higenamine • procaterol • terbutaline
EXEMPTIONS
• Inhalation salbutamol: a maximum of 1600 micrograms per 24 hours in separate doses not exceeding 600 micrograms within 8 hours of any dose;
• inhalation formoterol: a maximum dose of 54 micrograms per 24 hours is delivered;
• Inhalation salmeterol: maximum 200 micrograms per 24 hours;
• Inhalation vilanterol: maximum 25 micrograms per 24 hours.
NOTE
The presence of salbutamol in urine in excess of 1000 ng / ml or formoterol in excess of 40 ng / ml does not correspond to the therapeutic use of the substance and will be considered a positive laboratory finding (AAF) unless a controlled pharmacokinetic study shows that the abnormal result was due to the therapeutic dose (inhalation) up to the above maximum dose.
S4 HORMON AND METABOLIC MODULATORS
_
The prohibited substances in classes S4.1 and S4.2 are specific substances.
Substances classified in classes S4.3 and S4.4 are non-specific substances.
The following hormone and metabolic modulators are prohibited.
_
Including:
• 2-androstenol (5--androst-2-en-17-ol) • androsta-1,4,6-trien-3,17-dione (androstatriendione) • 2-androstenone (5---androst-2-en-17-one) • androsta-3,5-dien-7,17-dione (arimistan) • 3-androstenol (5--androst-3-end-17-ol) • exemestane • 3-androstenone (5--androst-3-en-17-one) • formestan • 4-androsten-3,6,17 trione (6-oxo) • Letozol • aminoglutetimide • testosterone • anastrozole
S4.2 ANTIEMROGENE SUBSTANCES [ANTIESTROGENES AND SELECTIVE MODULATORS OF ESTORGENE RECEPTORS (SERMS)]
Including:
• arformoterol • indacaterol • reproterol • tretoquinol (trimethoquinol) • phenoterol • levosalbutamol • salbutamol • tulobuterol • formoterol • olodaterol • salmeterol • vilanterol • higenamine • procaterol • terbutaline
S4.3. SUBSTANCES DETERMINING THE ACTIVATION OF THE RECEPTOR OF ACTIVINE IIB
Including:
• antibodies neutralising the activin A • myostat inhibitors, e.g.: • active IIB receptor competitors, e.g.: - agents reducing or disrupting the expression of myostine-false active receptors (e.g. ACE-031) - myostat binding proteins (e. g. follistatin, propeptide myostat) • antibodies against the activated IIB receptor (e. g. bimagrumab) - neutralising myostat antibodies or precursors (e. g. apitegromab, domagro zumab, landoguomab, stamulumab)
S4.4. METABOLIC MODULATORS
S4.4.1activators of AMP-activated proteinkinase (AMPK) such as AICAR, peroxisome proliferators of the activated delta receptor (PPARδ), e.g. 2- (2- methyl-4- ((4- methyl-2- (4- (trifluoromethyl) phenyl) thiazol-5-yl) methylthio phenoxy) acetic acid (GW1516, GW501516) and Rev-erbrelate agonists, e.g. SR9009, SR9011S4.2insulins and mimetics of insulins S4.4.3meldonium S4.4.4trimetazidine
S5 DIURETIC AND MASCING SUBSTANCES
_
All the prohibited substances in this class are specific substances.
All diuretics and cloaking agents, including all optical isomers such as d- and l, are prohibited.
Including:
• Diuretics such as: acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrylic acid; furosemide; indapamid; metolazone; spironolactone; thiazides such as bendroflumethiazide, gendide and hydrochlorothiazide; torasemide; triamterene; • Vaptans, e.g. conivaptan, movaptan, tolvaptan; • Intravenous plasma expanders such as: albumin, dextran, hydroxyethyl starch, mannitol; • Desmopressin; • Probenecid;
and other substances with similar chemical structure or similar biological effects.
EXEMPTIONS
• drospirenone; zambromo; and topical ophthalmologic administration of carbohydrate inhibitors (e. g. dorzolamide, brinzolamide);
• local administration of felypressin in dental anaesthesia.
NOTE
The finding of any quantity of a substance with a defined threshold limit: for formoterol, salbutamol, catin, ephedrine, methylephedrine and pseudoephedrine in the Sporto Sample at any time or, as the case may be, in competition with a diuretic or other cloaking agent (except for local ocular administration of a carbohydrate inhibitor or local administration of felypressin in dental anaesthesia), will be considered as a positive laboratory finding (AAF) unless Sportovec has an approved therapeutic exception (TV) to that substance which has already been granted for a diuretic or other cloaking agent.
PROHIBITED METHODS
_
All prohibited methods in this class are Inspecific except methods in M2.2, which are Specific methods.
INDIVIDUAL MANIPULATIONS WITH FISH AND CRUDE COMPOUNDS
The prohibition is as follows:
M1.1. Administration or re-introduction of any amount of autologous, allogeneic (homologous) or heterologous blood or red blood products of any origin into the circulatory system, with the exception of the donation of plasma or its constituents to athletes via plasmapheresis carried out in a registered sampling centre. M1.2. Artificial increase in intake, transmission or supply of oxygen. Including: Perfluorochemicals; efaproxial (RSR13); voxelotor and modified haemoglobin products such as blood substitutes based on hemoglobin and microcapsulated hemoglobin products, with the exception of additional oxygen inhalation. M1.3. Any form of intravascular handling of blood or blood components by physical or chemical means.
M2. CHEMICAL AND PHYSICAL MANIPULATION
The prohibition is as follows:
M2.1. Cheating or attempted fraud to violate the integrity and validity of samples taken during Doping Control. Among other things including: replacement and / or modification of the sample, e.g. by adding protease to the sample. M2.2. Intravenous infusion and / or injection of more than 100 ml in a total of 12 hours except those legally received during hospital treatment, surgery or clinical diagnostic examinations.
M3. GENE AND CURRENT LETTING
Due to the potential increase in sports performance, the following is prohibited:
M3.1. Use of nucleic acids or their analogues that may alter genome sequences and / or gene expression by any mechanism. This includes, inter alia, gene modification technologies, gene silencing and gene transfer technologies. M3.2. Use of normal or genetically modified cells.
S6 STIMULANCIA
_
All prohibited substances in this class are specific substances except those listed in S6.A, which are non-specific substances.
Drugs in this section: cocaine and methylenedioxymethamphetamine (MDMA / "ecstasy")
All stimulants, including all optical isomers such as d- and l, are prohibited.
Stimulants include:
_
• adrafinil • fonturacetam [4-phenylpiracetam (carfedone)] • amphetamine • furfenorex • amphetamine • lisdexamfetamine • amphetamine • mefenorex • amifenazol • mefentermine • benfluorex • mesocarb • benzylpiperazine • methamphetamine (d-) • bromoantane • p-methylamphetamine • clobenzorex • modafinil • cocaine • norfenfluramine • cropropamide • fendimetrazine • crotetamide • phentermine • fencamine • prenylamine • phenetylline • prolintane • fenfluramine • fenproproporex
Stimulans not specifically mentioned in this section are a specific substance.
S6.B: SPECIFIC STIMULANCIA
Including:
20 mg / kg / day
and other substances with similar chemical structure or similar biological effects
EXEMPTIONS
• clonidine;
• imidazolin derivatives in the case of their skin, nasal, eye or ear uses (e. g. brimonidine, clonazoline, phenoxazoline, indanazoline, napazoline, oxymethazoline, tetryzoline, tramazoline, xylomethazoline) and stimulants included in the monitoring programme 20245).
S7 Narcotics
_
All the prohibited substances in this class are specific substances.
Addictive substances in this section: diamorphine (heroin)
The following narcotics, including their possible optical isomers, e.g. d- and l, are prohibited.
• buprenorphine
S8 CANABINOIDES
_
All the prohibited substances in this class are specific substances. Additives in this section: tetrahydrocanabinol (THC)
All natural and synthetic canabinoids are prohibited, e.g.
• cannabis (hash, marijuana) and cannabis products
• Natural and synthetic tetrahydrocanabionols (THC)
• synthetic canabinoids mimicking THC effects
EXEMPTIONS
• canabidiol
S9 GLUCOCORTICOIDES
_
All the prohibited substances in this class are specific substances.
All glucocorticoids are prohibited if any injection, oral [including oromucosal (e. g. buccal, gingival, sublingual)] or rectal is administered.
Including:
• beclomethasone • dexamethasone • momethasone • betamethasone • flunisolide • prednisolone • budesonide • fluocortolone • prednisone • ciclesonide • fluticasone • triamcinolone acetonide • cortisone • hydrocortisone • deflazacort • methylprednisolone
NOTE
• Other routes of administration (including inhalation and topical: dental-intracranial, dermal, intranasal, ophthalmological, ear and peripheral) are not prohibited when used within the recommended doses and therapeutic indications by the manufacturer.
P1 BETA-BLOCATORS
PROHIBITED IN CERTAIN SPORTS
All the prohibited substances in this class are specific substances.
Beta-blockers are only banned in the following sports During the Competition and where it is marked with the symbol (*) and Outside the Competition. • archery (WA) * • skiing / snowboarding (FIS) - ski jumps, acrobatic jumps / U-ramp and snowboardU-ramp / big air • car sport (FIA) • underwater sports (CMAS) * in free diving, hunting and target shooting • billiards (all disciplines) (WCBS) • darts (WDF) • golf (IGF) • mini golf (WMF) • shooting (ISSF, IPC) *
* banned also outside competition
Including:
• acebutolol • bunolol • labetalol • oxprenolol • alprenolol • carteolol • metipranolol • pindolol • atenolol • carvedilol • metoprolol • propranolol • betaxolol • celiprolol • nadolol • sotalol • bisoprolol • esmolol • nebivolol • timolol
Příloha č. 2
Annex No 2
Text of the international contract in the relevant language
1) catin (d-norpseudoephedrine) and its L-isomer: is prohibited only at concentrations in urine greater than 5 micrograms per ml.
2) pseudoephedrine: prohibited only at concentrations in urine greater than 150 micrograms per ml.
3) ephedrine and methylephedrine: prohibited at concentrations in urine greater than 10 micrograms per ml.
4) epinephrine (adrenaline): no topical use such as nasal, ocular or concomitant use with local anaesthetics is prohibited.
5) Bupropion, phenylephrine, phenylpropanolamine, caffeine, nicotine, pipradrol and synephrine: the following substances are included in the monitoring programme 2024 and are not considered as prohibited substances.
Sign in for notes, favorites and notifications
Regulation Information
| Citation | Communication from the Ministry of Foreign Affairs No. 19 / 2025 Coll., amending and supplementing the Communication from the Ministry of Foreign Affairs No. 58 / 2007 Coll. s. and No. 46 / 2008 Coll. s. s. |
|---|---|
| Regulation Type | - |
| Author | - |
| Collection | Code of Laws |
| Date of Promulgation | 28.01.2025 |
|---|---|
| Effective from | 18.06.2024 |
| Effective until | - |
| Status | Valid |
The regulation text is for informational purposes only.
Comments 0